Research progress of Chinese and western medicine in the diagnosis and treatment of epidermal growth factor receptor-tyrosine kinase inhibitors-related oral mucositis

NIAN Jiayun; YANG Guowang; WANG Xiaomin

doi:10.16025/j.1674-1307.2025.02.027

您当前的位置：

首页 >

文章列表页 >

Research progress of Chinese and western medicine in the diagnosis and treatment of epidermal growth factor receptor-tyrosine kinase inhibitors-related oral mucositis

更新时间：2025-03-19

- Research progress of Chinese and western medicine in the diagnosis and treatment of epidermal growth factor receptor-tyrosine kinase inhibitors-related oral mucositis
- Beijing Journal of Traditional Chinese Medicine Vol. 44, Issue 2, Pages: 242-245(2025)
- 作者机构：
  
  首都医科大学附属北京中医医院肿瘤科，北京 100010
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2025.02.027
  CLC：
- Received：10 April 2024，
  
  Published：25 February 2025
- 稿件说明：
移动端阅览
念家云，杨国旺，王笑民.EGFR-TKI相关口腔黏膜炎的中西医诊治研究进展［J］.北京中医药，2025，44（2）：242-245.

NIAN Jiayun,YANG Guowang,WANG Xiaomin.Research progress of Chinese and western medicine in the diagnosis and treatment of epidermal growth factor receptor-tyrosine kinase inhibitors-related oral mucositis[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):242-245.
念家云，杨国旺，王笑民.EGFR-TKI相关口腔黏膜炎的中西医诊治研究进展［J］.北京中医药，2025，44（2）：242-245. DOI： 10.16025/j.1674-1307.2025.02.027.

NIAN Jiayun,YANG Guowang,WANG Xiaomin.Research progress of Chinese and western medicine in the diagnosis and treatment of epidermal growth factor receptor-tyrosine kinase inhibitors-related oral mucositis[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):242-245. DOI： 10.16025/j.1674-1307.2025.02.027.

摘要

表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）目前已广泛用于治疗EGFR突变晚期非小细胞肺癌，口腔黏膜炎（OM）是EGFR-TKI常见不良反应之一，各代EGFR-TKI相关OM发生率不尽相同（10%~70%），其中第二代药物相关OM的总发生率和三级以上OM发生率尤为显著。EGFR-TKI相关OM发生的时间多在服药2周左右，通常表现为阿弗他口腔溃疡，多伴有疼痛、口干、灼烧感、味觉改变等症状，不仅降低患者生活质量，且影响其治疗依从性和耐受性，甚至导致治疗中断。EGFR-TKI相关OM属中医学“口疮、口糜”范畴，发生机制与该药物性偏温燥、耗伤阴液有关，治疗上首倡从火论治，清上焦实火，降下焦虚火，虚实分治，三焦定位，展现了中医药治疗该病的优势。

Abstract

关键词

Keywords

references

HUANG L , JIANG S , SHI Y . Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020) [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 143 .

中国临床肿瘤学会指南工作委员会 . 非小细胞肺癌诊疗指南2021 [M ] . 北京 : 人民卫生出版社 , 2021 : 15 - 20 .

JIA Y , YUN CH , PARK E , et al . Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors [J ] . Nature , 2016 , 534 ( 7605 ): 129 - 132 .

LU S , DONG X , JIAN H , et al . AENEAS: a randomized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations [J ] . J Clin Oncol , 2022 , 40 ( 27 ): 3162 - 3171 .

PARK K , TAN EH , O'BYRNE K , et al . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J ] . Lancet Oncol , 2016 , 17 ( 5 ): 577 - 589 .

SORIA JC , FELIP E , COBO M , et al . Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial [J ] . Lancet Oncol , 2015 , 16 ( 8 ): 897 - 907 .

RAMALINGAM S , JÄNNE P , MOK T , et al . Dacomitinib versus erlotinib in patients with advanced-stage,previously treated non-small-cell lung cancer(ARCHER 1009):a randomised,double-blind,phase 3 trial [J ] . Lancet Oncol , 2014 , 15 ( 12 ): 1369 - 1378 .

LI X , ZHANG L , JIANG D , et al . Routine-dose and high-dose icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21-L858R mutation: the randomized, phase Ⅱ,increase trial [J ] . Clin Cancer Res , 2020 , 26 ( 13 ): 3162 - 3171 .

SHI Y , ZHANG L , LIU X , et al . Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN):a randomised, double-blind phase 3 non-inferiority trial [J ] . Lancet Oncol , 2013 , 14 ( 10 ): 953 - 961 .

SEQUIST L , YANG J , YAMAMOTO N , et al . Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations [J ] . J Clin Oncol , 2013 , 31 ( 27 ): 3327 - 3334 .

ELLIS P , SHEPHERD F , MILLWARD M , et al . Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial [J ] . Lancet Oncol , 2014 , 15 ( 12 ): 1379 - 1388 .

WU YL , TSUBOI M , HE J , et al . Osimertinib in resected EGFR-mutated non-small-cell lung cancer [J ] . N Engl J Med , 2020 , 383 ( 18 ): 1711 - 1723 .

RAMALINGAM S , VANSTEENKISTE J , PLANCHARD D , et al . Overall survival with osimertinib in untreated,EGFR-mutated advanced NSCLC [J ] . N Engl J Med , 2020 , 382 ( 1 ): 41 - 50 .

ARRIOLA E , REGUART N , ARTAL A , et al . Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel [J ] . Future Oncol , 2015 , 11 ( 2 ): 267 - 277 .

VIGARIOS E , EPSTEIN JB , SIBAUD V . Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors [J ] . Support Care Cancer , 2017 , 25 ( 5 ): 1713 - 1739 .

肖妍荻 , 杨华梅 , 但红霞 . 抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策 [J ] . 国际口腔医学杂志 , 2018 , 45 ( 2 ): 140 - 144 .

刘婷 , 黄帆 , 王文梅 . EGFR-TKIs药物相关口腔炎病例报告及相关文献复习 [J ] . 临床口腔医学杂志 , 2019 , 35 ( 7 ): 434 - 438 .

ELAD S , YAROM N , ZADIK Y , et al . The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies [J ] . CA Cancer J Clin , 2022 , 72 ( 1 ): 57 - 77 .

王文梅 , 段宁 . EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展 [J ] . 口腔医学研究 , 2021 , 37 ( 10 ): 869 - 874 .

胡洁 , 林丽珠 , 骆肖群 , 等 . EGFR-TKI不良反应管理专家共识 [J ] . 中国肺癌杂志 , 2019 , 22 ( 2 ): 57 - 81 .

ELAD S , CHENG K , LALLA R . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [J ] . Cancer , 2020 , 126 ( 19 ): 4423 - 4431 .

熊志刚 , 张策策 , 王晓伟 , 等 . 国医大师李士懋温阳法治疗口腔溃疡经验 [J ] . 中国中医基础医学杂志 , 2021 , 27 ( 9 ): 1483 - 1486 .

李东玲 , 周京旭 . 分子靶向药物所致阿弗他样口腔溃疡的三焦辨证 [J ] . 环球中医药 , 2019 , 12 ( 10 ): 1536 - 1537 .

王蒙 . 肺癌靶向治疗后的中医证候分析 [D ] . 北京 : 北京中医药大学 , 2014 .

许海柱 , 孙建立 , 张璇 . EGFR-TKI治疗后非小细胞肺癌中医证候研究 [J ] . 中国中西医结合杂志 , 2017 , 37 ( 9 ): 1050 - 1053 .

张璐 . 中晚期肺腺癌EGFR基因突变中医证型与骨转移的关联性研究 [D ] . 成都 : 成都中医药大学 , 2020 .

施展 , 金志超 , 花宝金 , 等 . 非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂不良反应的中医辨治 [J ] . 北京中医药 , 2018 , 37 ( 12 ): 1119 - 1121 .

何杰 , 花宝金 . 花宝金辨治肺癌靶向药相关性皮疹经验 [J ] . 辽宁中医杂志 , 2020 , 47 ( 2 ): 51 - 53 .

陆淑瑾 . 中医药联合埃克替尼治疗晚期非小细胞肺癌的疗效及其中医证型动态变化研究 [D ] . 杭州 : 浙江中医药大学 , 2015 .

张心悦 . 表皮生长因子受体拮抗剂相关皮肤不良反应的变化规律及中医证型变化的临床研究 [D ] . 北京 : 北京中医药大学 , 2014 .

刘嫦 , 唐建清 , 彭巍 . 唐建清从脾论治肺癌靶向药物所致口腔溃疡经验 [J ] . 中医临床研究 , 2022 , 14 ( 13 ): 95 - 97 .

王珏 , 邵科钉 , 林胜友 . 林胜友教授从“阴火论”论治恶性肿瘤靶向治疗后口腔溃疡的经验 [J ] . 浙江中医药大学学报 , 2019 , 43 ( 6 ): 584 - 586,590 .

沈悦忠 . 从“阴火论”论治恶性肿瘤靶向药物治疗后口腔溃疡的临床研究 [D ] . 杭州 : 浙江中医药大学 , 2022 .

彭昭文 , 刘鹏 , 易舒婧 , 等 . 加味地榆散治疗肺癌靶向治疗患者口腔黏膜炎阴虚热毒证的临床观察 [J ] . 现代中医临床 , 2021 , 28 ( 5 ): 34 - 37 .

林丽珠 . 中医药在EGFR-TKIs相关不良反应管理中的应用 [J ] . 中国中西医结合杂志 , 2019 , 39 ( 2 ): 144 - 147 .

念家云 , 富琦 , 王笑民 . 傅山引火汤加减治疗EGFR-TKIs相关口腔黏膜炎阴虚火旺证的疗效观察 [J ] . 时珍国医国药 , 2023 , 34 ( 2 ): 380 - 382 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Differentiation and treatment of chemotherapy and radiotherapy-induced oral mucositis based on the concept of “pain, itch, and sores belonging to heart”

A case of EGFR complex rare mutation in lung cancer treated with integrated Chinese and western medicine

Mechanism of “activating blood and resolving phlegm” method in the prevention and treatment of EGFR-TKI resistance in lung cancer

Related Author

QIANG Rui

PANG Bo

ZHANG Ge

LIU Shui-qingqing

LU Wen-ping

HU Jia-qi

QIN Xiao-yan

HOU Wei

Related Institution

北京中医医院顺义医院肿瘤科

中国中医科学院广安门医院国际医疗部

中国中医科学院广安门医院肿瘤科

北京中医药大学

⁰